艾司西酞普兰联合认知疗法治疗抑郁症对照研究

目的探讨艾司西酞普兰联合认知疗法治疗抑郁症的临床疗效。方法将100例抑郁症患者随机分为两组，每组50例，研究组实际完成49例，对照组实际完成48例，两组均口服艾司西酞普兰治疗，研究组在此基础上联合认知疗法治疗，观察8周。于治疔前及治疗后采用症状自评量表、汉密顿抑郁量表对两组进行测评分析。结果治疗4周末起，两组症状自评量表各因子分及汉密顿抑郁量表总分显著低于治疗前（P〈0．01）；同期两组间比较，治疗前两组各量表评分差异无显著性（P〉0．05），治疗4周末起研究组症状自评量表躯体化、强迫、抑郁、焦虑、敌对、恐怖、偏执因子分及汉密顿抑郁量表总分较对照组下降更显著（P〈0.05或0．01）；治疗8周末，研究组显效率为81．63％，对照组为62．50％，两组显效率比较差异有显著性（χ^2=4．42，P〈0．05）。结论艾司西酞普兰联合认知疗法能显著改善抑郁症患者的抑郁症状，提高其心理健康水平，优于单用艾司西酞普兰治疗。

A control study of escitalopram combined with cognitive therapy in depression

Objective To explore the efficacy of escitalopram combined with cognitive therapy （CT） in depression. Methods A total of 100 depression patients were randomly assigned to two groups of 50 ones each, 49 ones completed in research and 48 did in control group, both groups took orally escitalopram, and on that basis research was plus CT for 8 weeks. Assessments and analyses were performed with the Symptom Checklist-90 （SCL-90） and Hamilton Depression Scale （HAMD） before and after treatment. Results Since the end of the 4^th week each factor score of the SCL-90 and total score of the HAMD were significantly lower compared with pretreatment （P〈0.01）; before treatment there were no significant group differences in scales＇ scores （P〉0.05）, such factors＇ score of the SCL-90 and total score of the HAMD lowered more significantly in research than in control group as somzatization, obsession, depression, anxiety, hostility, phobias and paranoia （P〈0.05 or 0.01） ; at the end of the 8th week obvious effective rate was respectively 81.63% in research and 62. 50% in control group, which showed significant difference （χ^2= 4.42,P〈0.05）. Conclusion Escitalopram plus CT could notably improve depressive symptoms of depression patient and raise patient＇s mental health level compared single escitalopram.